Impax Announces Sale of Daraprim® to Turing Pharmaceuticals AG

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. ABBV
2. SPCX
3. MU
4. ACN
5. IBM
6. SPY
7. TSLA
8. DPZ
9. NVDA
10. PRIM

Go back to Impax Announces Sale of Daraprim® to Turing Pharmaceuticals AG

Leerink Partners Cuts Price Target on Impax Laboratories (IPXL) Following 2Q15

August 11, 2015 9:05 AM EDT

Leerink Partners maintained a Market Perform rating on Impax Laboratories (NASDAQ: IPXL), and cut the price target to $47.00 (from $49.00), following its 2Q15 earnings report. IPXL reported revenue of $214m compared to the Street's $200m estimate. IPXL lowered its 2015 GM guidance, now in the low 50s (vs.... More

Impax Laboratories (IPXL) Misses Q2 EPS by 1c

August 10, 2015 6:46 AM EDT

Impax Laboratories (NASDAQ: IPXL) reported Q2 EPS of $0.34, $0.01 worse than the analyst estimate of $0.35. Revenue for the quarter came in at $214.2 million versus the consensus estimate of $199.93 million.

For earnings history and earnings-related data on Impax Laboratories (IPXL) click here.

... More

Impax Laboratories (IPXL) Sells Daraprim U.S. Rights in $55M Deal

August 10, 2015 6:31 AM EDT

Impax Laboratories (NASDAQ: IPXL) announced that it has sold its U.S. rights to the Daraprim brand to Turing Pharmaceuticals AG for approximately $55 million.

Impax acquired Daraprim as part of the Company's acquisition of Tower Holdings, Inc. (including operating subsidiaries CorePharma LLC and Amedra... More